Safety of loncastuximab tesirine-lpyl in diffuse large B-cell lymphoma with severe hepatic dysfunction.
Sign Up to like & getrecommendations! Published in 2023 at "Cancer"
DOI: 10.1002/cncr.34816
Abstract: Diffuse large B-cell lymphoma (DLBCL) is an aggressive subtype of non-Hodgkin lymphoma with a high rate of disease relapse despite the achievement of clinical responses to frontline chemoimmunotherapy treatments. Loncastuximab tesirine-lpyl is a novel anti-CD19… read more here.
Keywords: tesirine lpyl; loncastuximab tesirine; diffuse large; severe hepatic ... See more keywords
A Phase I Study of ADCT-402 (Loncastuximab Tesirine), a Novel Pyrrolobenzodiazepine-Based Antibody–Drug Conjugate, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
Sign Up to like & getrecommendations! Published in 2019 at "Clinical Cancer Research"
DOI: 10.1158/1078-0432.ccr-19-0711
Abstract: Purpose: ADCT-402 (loncastuximab tesirine) is an antibody–drug conjugate comprising a CD19-targeting antibody and pyrrolobenzodiazepine dimers. A first-in-human study evaluated the safety and preliminary clinical activity of loncastuximab tesirine in patients with B-cell non-Hodgkin lymphoma (NHL).… read more here.
Keywords: loncastuximab tesirine; drug; tesirine; dose escalation ... See more keywords
Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma: a review of clinical data
Sign Up to like & getrecommendations! Published in 2022 at "Therapeutic Advances in Hematology"
DOI: 10.1177/20406207221087511
Abstract: Loncastuximab tesirine-lpyl (ADC Therapeutics) is an anti-CD19 antibody-drug conjugate which consists of anti-CD19 antibody and cytotoxic alkylating agent, SG3199. Data from preclinical in vitro and animal studies demonstrated its selectivity and efficacy. The phase I… read more here.
Keywords: cell; refractory; refractory diffuse; relapsed refractory ... See more keywords
Final Results of a Phase 1 Study of Loncastuximab Tesirine in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma.
Sign Up to like & getrecommendations! Published in 2020 at "Blood"
DOI: 10.1182/blood.2020007512
Abstract: The prognosis for patients with relapsed or refractory (R/R) B-cell non-Hodgkin lymphoma (B-NHL) remains poor, with a need for alternatives to current salvage therapies. Loncastuximab tesirine (ADCT-402) is an antibody-drug conjugate comprising a humanized anti-CD19… read more here.
Keywords: relapsed refractory; lymphoma; cell; study ... See more keywords
The antibody-drug conjugate loncastuximab tesirine for the treatment of diffuse large B-cell lymphoma
Sign Up to like & getrecommendations! Published in 2022 at "Blood"
DOI: 10.1182/blood.2021014663
Abstract: In this Blood Spotlight, Calabretta and colleagues describe the mechanism of action of loncastuximab tesirine, an anti-CD19 antibody-drug conjugate. They discuss data from the first phase 1 and 2 trials of the drug in patients… read more here.
Keywords: loncastuximab tesirine; large cell; diffuse large; drug conjugate ... See more keywords
Loncastuximab tesirine for diffuse large B-cell lymphoma.
Sign Up to like & getrecommendations! Published in 2021 at "Drugs of today"
DOI: 10.1358/dot.2021.57.12.3352741
Abstract: Loncastuximab tesirine-lpyl (ADC Therapeutics), an anti-CD19 antibody-drug conjugate, was recently approved for the treatment of relapsed, refractory diffuse large B-cell lymphoma on the basis of the results of a phase II clinical trial, LOTIS-2. Preclinical… read more here.
Keywords: cell lymphoma; diffuse large; cell; loncastuximab tesirine ... See more keywords